Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CCR9 | P51686 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RORB | Q92753 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700263 | 0.80 | KMT2A (0.64) | PTGS2PTGS1KMT2AALDH1A1RAB9A | |
| SCHEMBL4958940 | 0.80 | RAB9A (0.45) | BDKRB1KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL4957447 | 0.78 | PTGS2 (0.57) | PTGS2PTGS1BDKRB1 | |
| SCHEMBL12143400 | 0.75 | KMT2A (0.55) | PTGS2BDKRB1KMT2AALDH1A1RAB9A | |
| SCHEMBL4958487 | 0.74 | CA12 (0.44) | PTGS2PTGS1SMN1; SMN2TP53 | |
| SCHEMBL28147345 | 0.73 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL8442044 | 0.73 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL10969548 | 0.72 | RORB (0.60) | PTGS2PTGS1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13483912 | 0.72 | BDKRB1 (0.49) | PTGS2BDKRB1KMT2AALDH1A1RAB9A | |
| SCHEMBL4217205 | 0.72 | PTGS2 (0.63) | PTGS2PTGS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542972-A4 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-01-23 | — | — | EP | claimed |
| US-20070238735-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITRODMED, INC. (US) | 2007-10-11 | — | — | US | claimed |
| EP-1542972-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-04-15 | — | — | US | claimed |
| WO-2004010945-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-05 | — | — | WO | claimed |
| EP-1542972-A4 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070238735-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITRODMED, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-7244753-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1542972-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-04-15 | — | — | US | disclosed |
| WO-2004010945-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | PTGS2 1/4885PTGS1 4/4885BDKRB1 539/4885 |
| US-20070238735-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGS1 | PTGS2 1/4885PTGS1 3/4885BDKRB1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.